NIH funds research on pan-coronavirus vaccines
The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, today awarded grants to Brigham and Women’s Hospital and two universities to research and develop vaccine candidates that provide broad protective immunity to multiple coronavirus strains.
“These new awards are designed to look ahead and prepare for the next generation of coronaviruses with pandemic potential,” said NIAID Director Anthony Fauci, M.D.
The Pan-Coronavirus Vaccine Development Program expects to award additional grants to projects in 2022.
Related News Articles
Headline
Pfizer’s COVID-19 vaccine booster for children under age 5 was 80.3% effective and well tolerated in a clinical trial involving 1,678 children who received the…
Headline
The Centers for Disease Control and Prevention yesterday recommended children age 5-11 receive a booster dose five months after completing the Pfizer COVID-19…
Headline
U.S. residents can order online eight more free at-home tests for COVID-19, the White House announced yesterday. People who have difficulty accessing the…
Headline
The Food and Drug Administration today authorized a single Pfizer COVID-19 booster dose for children aged 5-11 who completed the Pfizer vaccine primary series…
Headline
The Food and Drug Administration yesterday approved using Olumiant (baricitinib) to treat COVID-19 in hospitalized adults requiring supplemental oxygen,…
Headline
The Food and Drug Administration last week extended to 24 months the shelf life for certain lots of refrigerated bamlanivimab. The combination monoclonal…